150 State St., Albany,
NY, USA, 12207
Technology has ever since its emergence, been making its mark in the healthcare field in a remarkable fashion. With cancer considered as the second leading cause of deaths globally, technology was prominently made to show promise with the introduction of various developments and advancements to tackle the same. One such introduction among others has been that of Liquid Biopsy.
A liquid biopsy, also known as fluid biopsy or fluid phase biopsy is a largely non-invasive sampling and analysis of non-solid biological tissue, primarily blood, for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science, namely, human genome sequencing and rising sensitivity of detecting techniques and assays. It is a test that could provide researchers, physicians and surgeons with information about the cancer profile of the patient and appropriate therapies to improve the survival rate of their patients.
Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers.
The biopsy probes into free-flowing circulating tumor cells, biomarkers most suited and being studied for viable commercial development are CTCs, circulating tumor DNA, and exosomes containing tumor DNA or RNA. Technologies under R&D include PCR-based assays for single gene analysis and NGS-based parallel gene analysis. And the three most potential biofluids under immense clinical observations for liquid biopsy sampling are blood, urine, and saliva.
This market is projected to expand at a mammoth CAGR in the next few years.
The growth of this market is attributed towards factors which include the increasing prevalence of cancer, preference of liquid biopsy over solid tumor biopsy, rise in awareness about minimally invasive procedures, favorable government initiatives, technological advancements, availability of funding for liquid biopsy R&D, rapid enhancements in NSG technology and increase in pre-screening programs etc.
The liquid biopsy will take a prominent position for cancer-related probe and investigation. It is rapidly substituting conventional tumor biopsies. The cancer information is obtained with the least amount of surgical invasion. Additionally, liquid biopsy reduces the apprehension of patients regarding pain. It also provides a safe and effective method for patients for whom a tissue biopsy is not possible due to associated risks.
Also, some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients, include easy and non-invasive access to the tumor genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment etc.
Liquid biopsy holds several other benefits over traditional cancer diagnostics techniques such as reduced cost, early prognosis, therapy monitoring, and detection of tumor heterogeneity, acquired drug resistance, and patient comfort.
Moreover, increasing funding for R&D in cancer is also expected to aid in growth of the market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.
However, some of the key factors restraining the growth of liquid biopsy market include alternatives to liquid biopsies, high cost of liquid biopsy, clinical utility challenges, varying levels of circulating free DNA (cfDNA) in serum and plasma, lack of sensitivity and specificity of liquid biopsy tests and unclear reimbursement & regulation scenarios.
LIQUID BIOPSY MARKET SEGMENTATION:
By Intended Audience:
By Circulating Biomarker:
By Clinical Application:
By End User:
By Sample Type:
While North America currently holding the largest share of the global liquid biopsy market, the Asia Pacific region is anticipated to be the largest potential market for the coming years. Owing to high incidence of cancer, growing demand for non-invasive treatment and rise in healthcare expenditure, the region is expected to experience fast-paced growth, in terms of both development and use of liquid biopsy tests and is also expected to grow at the highest CAGR.
FEW KEY PLAYERS IN LIQUID BIOPSY MARKET:
Timeline Considered for Analysis:
- 2019: Base Year
- 2020: Estimated Year
- 2020 to 2025: Forecast Period
Research Scope and Deliverables
Overview & Executive Summary
Market Drivers, Trends, Challenges and Opportunities
Market Size and Forecast Projections
Macroeconomic Indicators of Various Countries Impacting the Growth of the Market
Extensive Coverage of Industry Players including Recent Product Launches and Market Activities
Porter’s Five Force Analysis
Market Segmentation Analysis:
Industry report analyses the global liquid biopsy market by the following segments:
- Intended Audience
- Circulating Biomarker
- Clinical Application
- End User
- Sample Type
Customization: We also offer customization’s in the industry report as per the company’s specific needs.
Key Questions Answered in the Global Liquid Biopsy Industry Report
The report offers a comprehensive insight on the Liquid Biopsy Market share, competitor landscape, market trends, growth, revenue, and key driver’s analysis with coverage of key players, top geographies, product types and end user.
Exhaustive secondary research and in-depth primary interviews with industry experts has been conducted to present qualitative and quantitative insights in the report.
We offer customizations as per client’s specific needs.